Every 10-Q that Health In Tech, Inc. (HIT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIT filings page.
Health In Tech, Inc. reported weaker results for the quarter and six months ended June 30, 2026. Total revenues were $8.1 million for the quarter and $16.8 million year-to-date, slightly below the prior-year periods, while cost of revenues rose sharply, compressing margins.
For the quarter, the company recorded a net loss of $2.5 million versus net income of $0.6 million a year earlier; for the first half, it reported a net loss of $4.1 million compared with net income of $1.1 million. Operating expenses increased across sales and marketing, general and administrative, and research and development, and included a $739,773 credit loss on other receivables tied to purchased Deferred Administrative Surplus.
Cash used in operating activities was $6.2 million for the first half of 2026, compared with $2.0 million provided in the prior-year period. The company strengthened liquidity via a March 2026 PIPE financing that raised net proceeds of $6.4 million and ended June with cash and cash equivalents of $6.5 million. A program with a major stop-loss carrier led to cumulative revenue reductions of about $4.0 million and $4.0 million of interim payments, and the carrier has asserted an additional potential adjustment of up to approximately $0.4 million that remains under negotiation.
Health In Tech, Inc. reports Q1 2026 results with total revenue of $8,771,646 and a net loss of $1,588,281, compared with net income in the prior-year quarter. Revenue grew mainly from fees, while underwriting modeling revenue declined.
Cost of revenues and operating expenses rose sharply, driven by higher sales and marketing, research and development, and amortization of capitalized software, compressing gross profit to $4,509,399. The company strengthened liquidity through a March 2026 PIPE, issuing 5,600,000 Class A shares at $1.25 per share for net proceeds of $6,381,000, lifting cash and cash equivalents to $10,325,208 at quarter end.
Health In Tech, Inc. reported Q3 2025 results, showing strong growth and continued profitability. Revenue reached $8,490,093, up from $4,458,921 a year ago, while gross profit rose to $5,143,816 from $3,479,293. Operating expenses increased to $4,650,293 from $3,040,411 as the company invested in growth and platform capabilities. Net income was $452,176, compared with $376,086 in Q3 2024.
For the nine months, revenue was $25,818,926 versus $14,586,342, with net income of $1,581,399 versus $814,629, reflecting expanded SMR program fees and higher ICE underwriting revenue. Cash and cash equivalents were $8,023,613, supported by $2,682,602 provided by operating activities and offset by $2,358,213 invested in software development. The company recorded contra revenue tied to a carrier portfolio adjustment of $1,413,345 in Q3 and $2,369,088 year-to-date, with an $869,088 refund liability recorded. As of November 10, 2025, shares outstanding were 45,208,808 Class A and 11,700,000 Class B.
Health In Tech, Inc. reported accelerating revenue and margin expansion for the six months ended June 30, 2025. Total revenues rose to $17.33 million from $10.13 million a year earlier, driven by higher fees and underwriting modeling services, producing gross profit of $11.67 million and net income of $1.13 million, up from $438,543. Cash and cash equivalents increased modestly to $8.14 million, supported in part by net IPO proceeds of $8.21 million received previously.
The balance sheet shows growth in non-current and other receivables to $3.85 million, reflecting purchases of deferred administrative surplus; accounts payable rose to $4.33 million. The company recognized a refund liability of $955,743 tied to a variable reconciliation clause with a carrier and recorded stock-based compensation expense of $1.20 million during the period. Significant customer and vendor concentrations and collection uncertainty on purchased receivables are material risks disclosed in the filing.